Author: Biosion, Inc.

Posted Date:

February 3, 2026

Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors

Biosion, Inc.

February 3, 2026